NextCure (NXTC) Other financing activities (2018 - 2026)

NextCure (NXTC) posted quarterly Other financing activities of $14000.0 for Q1 2026, down 17.65% quarter-over-quarter from $17000.0 in Q4 2025.

NextCure (NXTC) Other financing activities (2018 - 2026) Analysis & Trends

NextCure's Other financing activities history runs 9 years deep, the most recent figure standing at $14000.0 for Q1 2026.

In Q1 2026, Other financing activities changed N/A year-over-year to $14000.0; the TTM figure through Mar 2026 stood at $32000.0 (changed N/A YoY), while the FY2025 annual figure was $36000.0, up 56.52% from the prior year.
Other financing activities for Q1 2026 stood at $14000.0, down from $17000.0 in the prior quarter.
The five-year high for Other financing activities was $144000.0 in Q4 2023, with the low at -$73000.0 in Q3 2023.
The 5-year median for Other financing activities is $13000.0 (2022), against an average of $17363.6.
The sharpest annual moves came in 2023 and 2025: Other financing activities slumped 942.86% in 2023, then soared 1600.0% in 2025.
NextCure's Other financing activities stood at -$7000.0 in 2022, then jumped by 2157.14% to $144000.0 in 2023, then slumped by 99.31% to $1000.0 in 2024, then jumped by 1600.0% to $17000.0 in 2025, then retreated by 17.65% to $14000.0 in 2026.
Business Quant data shows NXTC's Other financing activities at $14000.0 in Q1 2026, $17000.0 in Q4 2025, and $1000.0 in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	NextCure	33.72 Mn	33.72 Mn	-

Download Data